Article
Immunology
Lee Cheng Phua, Horace C. W. Choi, Joseph Wu, Mark Jit, Jeffrey Low, Kwong Ng, Fiona Pearce, Cameron Hall, Mohamed Ismail Abdul Aziz
Summary: This study evaluated the cost-effectiveness of replacing the bivalent HPV vaccine with the nonavalent HPV vaccine in the national school-based HPV vaccination program in Singapore. Results showed that the nonavalent vaccine had an ICER of S$61,629 per quality-adjusted life year gained in the base case, indicating that it may not be a cost-effective option compared to the bivalent vaccine for school-based HPV vaccination of 13-year old female students in Singapore. Considerable price reductions would be necessary to justify its inclusion in the school-based program in the future.
Article
Immunology
Dean Langsam, Dor Kahana, Erez Shmueli, Dan Yamin
Summary: The study suggests that adjusting the vaccination schedule can reduce pertussis incidence and healthcare visits, increasing maternal vaccination coverage is cost-effective, while the contribution of the second booster dose is limited.
Article
Immunology
Supitcha Kamolratanakul, Punnee Pitisuttithum
Summary: Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to various cancers. HPV vaccines have been proven to be safe and highly effective in preventing HPV infections and associated cancers, especially among young women. The different types of HPV vaccines have shown similar efficacy in protecting against certain HPV types, with the nonavalent vaccine offering additional protection against more types. HPV vaccination has also been shown to provide herd protection and reduce the prevalence of HPV-related cancers.
Review
Biotechnology & Applied Microbiology
Mallory K. Ellingson, Hassan Sheikha, Kate Nyhan, Carlos R. Oliveira, Linda M. Niccolai
Summary: Human papillomavirus (HPV) vaccines are most effective when administered at younger ages, preventing infections prior to natural exposure. A systematic review of HPV vaccine effectiveness studies published between 2007 and 2022 found that the highest vaccine effectiveness was observed in the youngest age group. Vaccine effectiveness estimates ranged from approximately 74% to 93% for younger adolescents ages 9-14 years and from 12% to 90% for adolescents ages 15-18 years. These findings emphasize the importance of on-time vaccination for optimal protection against HPV-related diseases.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Obstetrics & Gynecology
C. Acuti Martellucci, S. Nomura, D. Yoneoka, P. Ueda, J. M. L. Brotherton, K. Canfell, M. Palmer, L. Manzoli, P. Giorgi Rossi, A. De Togni, C. Palmonari, A. Califano, E. Saito, M. Hashizume, K. Shibuya
Summary: This retrospective cohort study in Italy assessed the effectiveness of an HPV vaccination programme in reducing the risk of cervical abnormalities detected during subsequent screenings. Results showed that women who received at least one dose of the HPV vaccine were significantly less likely to have abnormal cervical cytology. Overall, catch-up HPV vaccination almost halved the risk of cytological abnormalities in organized cervical screening programmes.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2021)
Article
Gastroenterology & Hepatology
Shevanthi Nayagam, Margaret J. de Villiers, Yusuke Shimakawa, Maud Lemoine, Mark R. Thursz, Nick Walsh, Timothy B. Hallett
Summary: In 2020, WHO recommended adding peripartum antiviral prophylaxis to hepatitis B vaccination to prevent mother-to-child transmission of HBV. This study evaluated the impact and cost-effectiveness of this recommendation and a simplified strategy of providing antiviral prophylaxis to all HBsAg-positive pregnant women. The findings suggest that the addition of peripartum antiviral prophylaxis could be cost-effective in many countries, especially if diagnostic costs are reduced.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Steven Simoens, Andre Bento-Abreu, Barbara Merckx, Sophie Joubert, Steve Vermeersch, Andrew Pavelyev, Stefan Varga, Edith Morais
Summary: Expanding HPV vaccination programs in Belgium to gender-neutral vaccination (GNV) with the 9-valent HPV vaccine can reduce the burden of HPV-related disease and deaths, and is cost-effective compared to female-only vaccination (FOV).
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Vincent Daniels, Vimalanand S. Prabhu, Cody Palmer, Salome Samant, Smita Kothari, Craig Roberts, Elamin Elbasha
Summary: The study evaluated the public health impact and cost-effectiveness of expanding catch-up HPV vaccination up to age 45, showing that this expansion would prevent tens of thousands of cases of cancer and other diseases, with a favorable cost-effectiveness ratio.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Medicine, General & Internal
Hannah G. Rosenblum, Rayleen M. Lewis, Julia W. Gargano, Troy D. Querec, Elizabeth R. Unger, Lauri E. Markowitz
Summary: This study estimated the impact and effectiveness of HPV vaccination on sexually experienced females and males in the United States. The results showed significant impact of the vaccine on the prevalence of quadrivalent HPV types, but no significant impact on non-quadrivalent HPV types. Vaccine effectiveness varied across different time periods and genders. The nationally representative data demonstrate the increasing effectiveness of the vaccination program and herd protection.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Immunology
Joske Hoes, Petra J. Woestenberg, Johannes A. Bogaards, Audrey J. King, Hester E. de Melker, Johannes Berkhof, Christian J. P. A. Hoebe, Marianne A. B. van der Sande, Birgit H. B. van Benthem
Summary: This study assessed trends in HPV prevalence over 8 years postvaccination among men and women in the Netherlands. Significant declines were observed in vaccine types HPV-16/18 among women, heterosexual men, and unvaccinated women, while increases were observed for certain HPV types in women and unvaccinated women. The results provide evidence of herd effects against HPV-16/18 among heterosexual men and cross-protective types, as well as herd effects against vaccine types among unvaccinated women.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Timothy Brennan, Anna Hidle, Reena H. Doshi, Qian An, Anagha Loharikar, Rebecca Casey, Ousseynou Badiane, Alassane Ndiaye, Aliou Diallo, Jerlie Loko Roka, Nelly Mejia, Taiwo Abimbola
Summary: This study evaluated the costs of Senegal's introduction of HPV vaccine. The total financial and economic delivery costs were found to be $1,152,351 and $2,838,466, respectively. A total of 375,608 HPV vaccine doses were administered during the cost evaluation.
Review
Immunology
Lauri E. Markowitz, Melanie Drolet, Rayleen M. Lewis, Philippe Lemieux-Mellouki, Norma Perez, Mark Jit, Julia M. Brotherton, Gina Ogilvie, Aimee R. Kreimer, Marc Brisson
Summary: This study provides a systematic literature review on the effectiveness of HPV vaccines. It highlights the biases in observational studies and the need for further research to obtain valid effectiveness estimates.
Article
Public, Environmental & Occupational Health
Liangru Zhou, Baiyang Gu, Jian Wang, Guoxiang Liu, Xin Zhang
Summary: This study evaluated the cost-effectiveness of including HPV vaccines in the Chinese immunization program. The results showed that HPV vaccines were cost-effective at the national level and in most provinces, with higher population provinces having more prevented cases and deaths. The economic situation of HPV vaccination differed at the provincial level, and provinces with limited ability to pay should seek subsidies from the state.
Article
Biotechnology & Applied Microbiology
Renata Linertova, Carmen Guirado-Fuentes, Javier Mar-Medina, Conor Teljeur
Summary: This study estimated the costs and benefits of HPV vaccination in Spain, comparing two types of vaccine, only in girls or in both genders. The analysis considered both direct and indirect protection provided by vaccination. The results suggest that vaccinating all adolescents may not be cost-effective, but including protection against additional cancers or reducing the vaccine price would make it worth vaccinating all adolescents in Spain. The study also highlighted ethical arguments supporting HPV vaccination for both genders.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Cecilia L. Llave, Maria Esterlita V. Uy, Hilton Y. Lam, Josephine G. Aldaba, Clarence C. Yacapin, Michelle B. Miranda, Haidee A. Valverde, Wilda T. Silva, Saira Nawaz, Rose C. Slavkovsky, Jessica Mooney, Elisabeth L. Vodicka
Summary: Cervical cancer is the second most common cancer among women in the Philippines. HPV vaccines provide protection against the most common cancer-causing HPV types. This study analyzed the cost-effectiveness of different HPV vaccine products and found that some vaccines were cost-effective from both government and societal perspectives, while GARDASIL (R) 9 was not cost-effective under any scenario.
Article
Public, Environmental & Occupational Health
Manrinder Kaur Tatla, Mette Tuxen Faber, Bo T. Hansen, Lisen Arnheim-Dahlstrom, Christian Munk, Mari Nygard, Susanne K. Kjaer
PREVENTIVE MEDICINE
(2020)
Article
Oncology
Dana Hashim, Birgit Engesaeter, Gry Baadstrand Skare, Philip E. Castle, Tone Bjorge, Ameli Trope, Mari Nygard
BRITISH JOURNAL OF CANCER
(2020)
Article
Mathematical & Computational Biology
Braden C. Soper, Mari Nygard, Ghaleb Abdulla, Rui Meng, Jan F. Nygard
STATISTICS IN MEDICINE
(2020)
Article
Oncology
Li Dong, Mari Nygard, Bo T. Hansen
Summary: This study in Norway aimed to assess the sociodemographic correlates of opportunistic and catch-up HPV vaccine uptake among women. Inequalities were found in both self-paid opportunistic and free-of-charge catch-up HPV vaccine uptake, with particularly low uptake among women with two immigrant parents and low household income. HPV vaccine uptake was strongly associated with sociodemographic background, highlighting the need to achieve equity in vaccination.
Review
Immunology
Wei Wang, Smita Kothari, Marc Baay, Suzanne M. Garland, Anna R. Giuliano, Mari Nygard, Christine Velicer, Joseph Tota, Anushua Sinha, Jozica Skufca, Thomas Verstraeten, Karin Sundstrom
Summary: Observational studies on vaccine effectiveness and impact are crucial for assessing the real-world effects of vaccines, with careful selection of study design, data sources, and analytical methods to mitigate bias. Global monitoring of public health interventions like HPV vaccination programs is becoming easier with access to real-world data, but robust methodology is needed to ensure accurate evaluation of vaccine effects and health policy decisions. A critical appraisal of methodology used in these studies can guide future research and evaluation of HPV vaccination programs globally.
EXPERT REVIEW OF VACCINES
(2022)
Article
Oncology
Mari Nyga, Birgit Engesaeter, Philip E. Castle, Jannicke Mohr Berland, Maj Liv Eide, Ole Erik Iversen, Christine Monceyron Jonassen, Irene Kraus Christiansen, Olav Karsten Vintermyr, Ameli Trope
Summary: This study compared the effectiveness of HPV-based screening protocol and liquid-based cytology (LBC) screening protocol in detecting cervical intraepithelial neoplasia (CIN) and cancer. The results showed that the HPV-based screening protocol was more effective in detecting CIN2, CIN3, and cancer than the LBC screening protocol. The effectiveness of both protocols varied with age, with better outcomes observed in women under 50 years old.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Hilary A. Robbins, Aida Ferreiro-Iglesias, Tim Waterboer, Nicole Brenner, Mari Nygard, Noemi Bender, Lea Schroeder, Allan Hildesheim, Michael Pawlita, Gypsyamber D'Souza, Kala Visvanathan, Hilde Langseth, Nicolas F. Schlecht, Lesley F. Tinker, Ilir Agalliu, Sylvia Wassertheil-Smoller, Eivind Ness-Jensen, Kristian Hveem, Sara Grioni, Rudolf Kaaks, Maria-Jose Sanchez, Elisabete Weiderpass, Graham G. Giles, Roger L. Milne, Qiuyin Cai, William J. Blot, Wei Zheng, Stephanie J. Weinstein, Demetrius Albanes, Wen-Yi Huang, Neal D. Freedman, Aimee R. Kreimer, Mattias Johansson, Paul Brennan
Summary: Seropositivity for HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. This study constructed an OPC risk prediction model and found that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Gunvor Aasbo, Ameli Trope, Mari Nygard, Irene Kraus Christiansen, Ingrid Baasland, Grete Alrek Iversen, Ane Cecilie Munk, Marit Halonen Christiansen, Gro Kummeneje Presthus, Karina Undem, Tone Bjorge, Philip E. Castle, Bo T. Hansen
Summary: This study aimed to investigate whether human papillomavirus (HPV) self-sampling can increase screening participation among long-term non-attenders in Norway. The results showed that opt-in and send-to-all self-sampling methods increased screening participation among long-term, higher-risk non-attenders. Moreover, the detection rate of high-risk HPV in self-samples was similar to that in clinician-collected samples.
BRITISH JOURNAL OF CANCER
(2022)
Review
Immunology
Wei (Vivian) Wang, Smita Kothari, Jozica Skufca, Anna R. Giuliano, Karin Sundstrom, Mari Nygard, Carol Koro, Marc Baay, Thomas Verstraeten, Alain Luxembourg, Alfred J. Saah, Suzanne M. Garland
EXPERT REVIEW OF VACCINES
(2022)
Article
Health Care Sciences & Services
Rui Meng, Braden Soper, Herbert K. H. Lee, Jan F. Nygard, Mari Nygard
Summary: Continuous-time hidden Markov models are a useful approach for disease modeling. Most applications use time-homogeneous models, but this assumption is too simplistic for accurately modeling disease progression. We consider the heterogeneity of disease progression and risks in the population using piece-wise constant intensity functions and a latent mixture structure. We propose an efficient algorithm for inference and demonstrate the superior performance of our method using synthetic data and a real-world cervical cancer screening dataset.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2022)
Article
Health Care Sciences & Services
Madleen Orumaa, Suzanne Campbell, Nathalie C. Stoer, Philip E. Castle, Sagar Sen, Ameli Trope, Adebola Adedimeji, Mari Nygard
Summary: Exposure to the FightHPV mobile app gamified educational content significantly increased cervical cancer screening attendance and improved detection of women with high risk for cervical cancer.
JMIR SERIOUS GAMES
(2022)
Editorial Material
Health Care Sciences & Services
Mari Nygard, Stale Nygard
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Li Dong, Mari Nygard, Nathalie C. Stoer, Ole Klungsoyr, Bo T. Hansen
Summary: This study conducted in Norway presents the first real-world effectiveness study of HPV vaccination on high-grade cervical lesions outside the routine program. The findings indicate that HPV vaccination is effective against high-grade cervical lesions among women vaccinated below age 20, but may not have the desired impact among women vaccinated at age 20 or older.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Letter
Oncology
Anna Tisler, Mari Nygard, Anda Kivite-Urtane, Natalija Berza, Jana Zodzika, Mindaugas Stankunas, Nicholas Baltzer, Kersti Paerna, Anneli Uuskuela
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Health Care Sciences & Services
Gunvor Aasbo, Bo T. Hansen, Jo Waller, Mari Nygard, Kari N. Solbraekke
Summary: This study used focus group interviews to explore how women in Norway who have postponed cervical cancer screening discuss the epidemiology and prevention of the disease. The findings showed that lay persons negotiate acceptable and nuanced explanations of cervical cancer using both biomedical concepts and cultural values. Uncertainty about risk factors was a key aspect of these negotiations. The study provides insights into the contexts in which screening may be considered less relevant or significant for maintaining health.